Asia Pacific Traumatic Brain Injury Treatment Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
792.23 Billion
USD
1.44 Billion
2024
2032
 Período de previsão |
2025 –2032 |
 Tamanho do mercado (ano base ) | USD 792.23 Billion |
 Tamanho do mercado ( Ano de previsão) | USD 1.44 Billion |
 CAGR |
% |
| Principais participantes do mercado |
Segmentação do mercado de tratamento de lesões cerebrais traumáticas na região Ásia-Pacífico, por tratamento (cirurgia, cuidados de emergência imediatos e medicamentos), via de administração (parenteral, oral e outros), idade do paciente (crianças, adolescentes e idosos), género (masculino e feminino), causa da lesão (quedas, trânsito de veículos motorizados, desporto e outros), utilizador final (hospitais, clínicas de neurologia, farmácias independentes e outros) - Tendências do setor e previsão até 2032
Tamanho do mercado de tratamento de lesões cerebrais traumáticas
- O mercado de tratamento de lesões cerebrais traumáticas na Ásia-Pacífico foi avaliado em 792,23 mil milhões de dólares em 2024 e deverá atingir 1,44 mil milhões de dólares até 2032.
- Durante o período previsto de 2025 a 2032, o mercado deverá crescer a um CAGR de 7,9%, impulsionado principalmente pela crescente incidência de lesão cerebral traumática (TCE).
- Este crescimento é impulsionado por fatores como o aumento da incidência de traumatismo cranioencefálico (TCE), a crescente adoção de procedimentos minimamente invasivos no tratamento do TCE, o que impulsiona a procura de tratamento do traumatismo cranioencefálico
Análise de Mercado de Tratamento de Lesões Cerebrais Traumáticas
- O mercado de tratamento de lesões cerebrais traumáticas (LCT) deverá expandir-se significativamente devido à crescente consciencialização sobre a LCT , aos avanços nas tecnologias de diagnóstico e à crescente incidência de acidentes e lesões desportivas, impulsionando a procura por opções de tratamento e terapias de reabilitação eficazes.
- O mercado está a assistir a um aumento de tratamentos inovadores , incluindo agentes neuroprotetores, terapias com células estaminais e tecnologias de reabilitação avançadas, que estão a melhorar os resultados da recuperação e a expandir o panorama terapêutico para os doentes com TCE.
- Os EUA destacam-se como um dos países dominantes no mercado de tratamento de lesões cerebrais traumáticas, impulsionado por infraestruturas de saúde avançadas, investimentos significativos em investigação e elevada prevalência de TCE
Âmbito do Relatório e Segmentação do Mercado de Tratamento de Lesões Traumáticas Cerebrais
|
Atributos |
Insights sobre o mercado de tratamento de lesões cerebrais traumáticas |
|
Segmentos abrangidos |
|
|
Países abrangidos |
Ásia-Pacífico
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Traumatic Brain Injury Treatment Market Trends
“Growing Adoption of Telemedicine in TBI Treatment”
- Telemedicine allows patients to receive remote consultations and rehabilitation services, improving access to specialized care for individuals in rural or underserved areas, thus facilitating timely intervention for TBI patients
- Utilizing telehealth reduces the costs associated with in-person visits, including travel expenses and lost productivity, making it a financially viable option for both patients and healthcare providers
- In March 2021, NCBI stated that Telehealth visits for patients with acquired brain injuries and their caregivers can ease the burden of transportation, improve compliance, and increase overall satisfaction. Management strategies are largely unaffected in the telehealth setting, and telerehab options have been found to be equal or superior to in-person therapy to treat many associated deficits
- Telemedicine platforms enable continuous monitoring and follow-up care, allowing healthcare professionals to track patient progress remotely, provide real-time feedback, and adjust treatment plans as necessary, ultimately enhancing patient outcomes in TBI management
Traumatic Brain Injury Treatment Market Dynamics
Driver
“Increasing Incidence of Traumatic Brain Injury (TBI)”
- As the number of cases continues to rise due to various contributing factors such as road accidents, sports-related injuries, and falls, particularly among the elderly population. Road traffic accidents remain one of the leading causes of TBI worldwide, with the growing number of vehicles on the road, reckless driving behaviours
- Sports-related injuries, particularly in contact sports like football, boxing, and rugby, have further fueled the surge in TBI cases, with increasing awareness of concussion-related complications prompting the need for advanced treatment solutions
For instance,
- In March 2025, as per the article published by ScienceDirect, there were 20.84 million incident cases and 37.93 million prevalent cases of Traumatic Brain Injury (TBI) globally, leading to 5.48 million, Years Lived With Disability (YLDs). The rising burden of TBI increases the demand for advanced treatments, driving investments in diagnostics, neurosurgery, and rehabilitation, ultimately fueling the growth of the global TBI treatment market
- In October 2024, according to the data published by Centers for Disease Control and Prevention, In 2021, there were 69,473 TBI-related deaths, and in 2020, approximately 214,110 hospitalizations occurred. This equates to over 586 hospitalizations and 190 deaths per day, with individuals aged 75+ and males being the most affected. The rising burden of TBI necessitates advanced treatment solutions, driving growth in the global TBI treatment market
- Factors such as road accidents, sports injuries, and falls—especially among the elderly—contribute to increase in TBI. Growing awareness and demand for advanced treatments, including neurosurgery, drug therapies, and rehabilitation, are fuelling market expansion and technological advancements in TBI management
Opportunity
“Rising Personalized and Targeted Therapies in Traumatic Brain Injury (TBI)”
- TBI is a highly variable condition influenced by severity, location, and patient-specific factors, making traditional treatments less effective. Advances in biomarker discovery, neuroimaging, and computational modeling help identify distinct injury patterns, enabling more targeted therapies. Pharmacogenomics enhances drug selection and dosing, minimizing side effects while maximizing effectiveness. Personalized rehabilitation strategies, tailored to cognitive and motor impairments, further optimize recovery by aligning treatments with individual healing trajectories
For instance,
- In February 2022, as per NCBI, researchers have discovered genetic risk factors like APOE4 and BDNF Val66Met polymorphisms that impact TBI recovery. By focusing on these variations, personalized treatments can lower harmful biomarkers, enhance neuroprotection, and improve rehabilitation. This approach tailors’ therapies to individual needs, ultimately leading to better long-term functional outcomes for TBI patients
- Em fevereiro de 2024, o artigo MDPI TBI apresenta uma oportunidade significativa para melhorar os resultados dos doentes. Os avanços na descoberta de biomarcadores, farmacogenómica e neuroimagiologia permitem tratamentos de precisão adaptados a perfis de lesões individuais. As terapias emergentes, incluindo a neuroestimulação e os tratamentos com células estaminais, alargam ainda mais as possibilidades de intervenções eficazes e específicas para cada doente no tratamento do TCE.
- As terapias personalizadas e dirigidas apresentam uma abordagem transformadora para o tratamento da Lesão Cerebral Traumática (LCT) ao adaptar as intervenções aos perfis genéticos e moleculares individuais. Estas estratégias centram-se em biomarcadores e processos celulares específicos para reduzir os danos secundários e melhorar a recuperação. Ao otimizar o tratamento, as terapias personalizadas melhoram os resultados e promovem a recuperação funcional a longo prazo dos doentes com TCE.
Restrição/Desafio
“Dificuldades em ultrapassar a barreira hematoencefálica para o tratamento do TCE”
- Um desafio significativo no tratamento do Traumatismo Cranioencefálico (TCE) é a rotura da Barreira Hematoencefálica (BHE). Após um TCE, a barreira hematoencefálica (BHE) fica geralmente comprometida, permitindo a entrada de substâncias nocivas no cérebro, o que pode agravar a lesão e dificultar a recuperação. Isto cria dificuldades na administração eficaz de agentes terapêuticos, limitando o sucesso de muitos tratamentos concebidos para auxiliar na recuperação e proteger o tecido cerebral.
- Além disso, restaurar a integridade da Barreira Hematoencefálica (BHE) sem causar danos adicionais continua a ser um grande desafio. O desenvolvimento de sistemas de administração direcionados que possam contornar a barreira danificada sem introduzir mais riscos é crucial para melhorar os resultados do tratamento do TCE.
Por exemplo,
- Em janeiro de 2022, a Springer Nature Publishing Inc informou que a barreira hematoencefálica (BHE) restringe a administração de agentes terapêuticos ao cérebro. Mesmo quando a BHE é comprometida após uma lesão, muitos medicamentos, principalmente moléculas grandes, ainda têm dificuldade em penetrá-la, limitando a eficácia dos tratamentos e complicando as terapêuticas dirigidas.
- Em junho de 2024, a Nature Reviews Neurology informou que a disfunção da BHE pode persistir dias a anos após o TCE, contribuindo para complicações neurológicas a longo prazo. Esta disfunção está associada a edema, neuroinflamação e alterações nas redes neuronais, complicando as estratégias de tratamento e levando a comprometimentos cognitivos, depressão e epilepsia pós-traumática, desafiando assim a recuperação eficaz e as abordagens terapêuticas.
- A rutura da barreira hematoencefálica (BHE) representa um desafio significativo no tratamento do traumatismo cranioencefálico (TCE), uma vez que restringe a administração eficaz dos tratamentos e agrava os danos cerebrais. A disfunção persistente da BHE pode levar a complicações a longo prazo, incluindo inflamação, inchaço cerebral e distúrbios cognitivos. Embora abordagens como a terapia de eliminação de ERO sejam promissoras na melhoria da função cerebral, a natureza flutuante dos danos da BHE complica as estratégias terapêuticas. Para melhorar os resultados do TCE, existe uma necessidade crítica de sistemas inovadores de administração de medicamentos e de melhores métodos para monitorizar a integridade da BHE, permitindo tratamentos mais eficazes e reduzindo as deficiências neurológicas a longo prazo.
Âmbito de mercado de tratamento de lesão cerebral traumática
O mercado é segmentado com base no tratamento, idade do paciente, sexo, causa da lesão e utilizador final.
|
Segmentação |
Sub-segmentação |
|
Por tratamento |
|
|
Por idade do doente |
|
|
Por género |
|
|
Por causa de lesão |
|
|
Por utilizador final |
|
Análise de Mercado de Tratamento de Lesões Cerebrais Traumáticas
“A China é a região dominante no mercado de tratamento de lesões cerebrais traumáticas”
- Espera-se que a China domine o mercado de tratamento de lesões cerebrais traumáticas, impulsionada por infraestruturas de saúde avançadas, maior sensibilização para a gestão de lesões cerebrais e investimento significativo em investigação e desenvolvimento
- A China detém uma quota significativa do mercado de tratamento de lesões cerebrais traumáticas, impulsionada pelos avanços na tecnologia médica, pela crescente incidência de lesões cerebrais e por uma infraestrutura de saúde robusta.
“ A China deverá registar a maior taxa de crescimento”
- Espera-se que a China testemunhe a maior taxa de crescimento no mercado de tratamento de lesões cerebrais traumáticas (LCT) na Ásia-Pacífico, impulsionado por rápidos avanços na infraestrutura de saúde, aumento da consciencialização sobre a gestão da LCT e a crescente adoção de terapias neuroprotetoras avançadas e soluções de reabilitação.
- A China está a emergir como um mercado importante devido ao envelhecimento da população, que é mais suscetível a distúrbios neurológicos, incluindo lesões cerebrais traumáticas. Além disso, a crescente incidência de acidentes rodoviários, lesões desportivas e TCE relacionados com militares está a aumentar ainda mais a procura de opções de tratamento inovadoras no mercado de tratamento de lesões cerebrais traumáticas (TCE) da Ásia-Pacífico.
Participação no mercado de tratamento de lesão cerebral traumática
O cenário competitivo do mercado fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, amplitude e abrangência do produto, domínio da aplicação. Os pontos de dados fornecidos acima estão apenas relacionados com o foco das empresas em relação ao mercado.
Os principais líderes de mercado que operam no mercado são:
- Pfizer, Lda. (EUA)
- Teva Pharmaceuticals US, Inc. (EUA)
- Fresenius SE & Co. KGaA (Fresenius Kabi AG) (Alemanha)
- Viatris Inc. (EUA)
- Amneal Produtos Farmacêuticos LLC. (NÓS)
- Laboratórios Dr. Reddy's Lda. (Índia)
- Sun Pharmaceutical Industries, Inc. (Índia)
- Lupin (Índia)
- Hikma (Jordânia)
- Aurobindo Pharma US (Índia)
- UCI Médica (EUA)
- B. Braun Medical Inc. (Alemanha)
- Alembic Pharmaceuticals Limited (Índia)
- Merz Therapeutics (Alemanha)
- Advacare (África do Sul)
- Maxzimaa (Índia)
- Jedux Parenteral Private Limited (Índia)
- Sagent Pharmaceuticals, Inc. (EUA)
- Swiss Pharma Nigeria Limited (Nigéria)
Últimos desenvolvimentos no mercado de tratamento de lesões cerebrais traumáticas
- Em fevereiro de 2024, a Viatris e a Idorsia estabeleceram uma importante colaboração de investigação e desenvolvimento na América do Norte para promover terapias inovadoras em diversas áreas terapêuticas. Esta parceria alavanca a experiência da Idorsia na descoberta de medicamentos e o alcance da Viatris na América do Norte, acelerando o desenvolvimento de tratamentos inovadores e expandindo os pipelines de ambas as empresas, reforçando o seu compromisso em satisfazer as necessidades médicas não satisfeitas em todo o mundo.
- Em fevereiro de 2021, a Fresenius Kabi expandiu as suas instalações na Áustria, reforçando as suas capacidades de produção e inovação em produtos farmacêuticos e tecnologias médicas. Esta expansão aumenta a eficiência do fabrico, garante um fornecimento constante de produtos de cuidados intensivos e apoia os avanços da investigação. Ao aumentar a capacidade e a excelência operacional, a empresa reforça a sua presença no mercado e satisfaz a crescente procura da América do Norte por soluções de saúde
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END-USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 TECHNOLOGY ROADMAP
4.4 VALUE CHAIN ANALYSIS
4.5 OPPUTUNITY MAP ANALYSIS
4.6 REIMBURSEMENT FRAMEWORK
4.7 COST ANALYSIS BREAKDOWN
4.8 PENETRATION AND GROWTH PROSPECT MAPPING: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
4.9 KEY PRICING STRATEGIES: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
4.1 MICRO AND MACRO-ECONOMIC FACTORS: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET
5 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING INCIDENCE OF TRAUMATIC BRAIN INJURY (TBI)
6.1.2 GROWING ADOPTION OF MINIMALLY INVASIVE PROCEDURES IN TBI TREATMENT
6.1.3 TECHNOLOGICAL ADVANCEMENT FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURIES (TBI)
6.1.4 ADVANCEMENTS IN NEUROPROTECTION AND PHARMACOTHERAPY FOR TBI TREATMENT
6.2 RESTRAINTS
6.2.1 SHORTAGE OF TRAINED NEUROLOGISTS AND NEUROSURGEONS
6.2.2 HIGH COST OF TRAUMATIC BRAIN INJURY (TBI) TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING PERSONALIZED & TARGETED THERAPIES IN TRAUMATIC BRAIN INJURY (TBI)
6.3.2 GROWING BRAIN STIMULATION TECHNIQUES IN TRAUMATIC BRAIN INJURY (TBI) TREATMENT
6.3.3 RISING ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN DIAGNOSING TRAUMATIC BRAIN INJURY (TBI)
6.4 CHALLENGES
6.4.1 DIFFICULTIES IN OVERCOMING THE BLOOD-BRAIN BARRIER FOR TBI TREATMENT
6.4.2 ABSENCE OF STANDARDIZED TREATMENT PROTOCOLS IN TRAUMATIC BRAIN INJURY MANAGEMENT
7 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 SURGERY
7.2.1 BRAIN BLEEDING TREATMENT
7.2.2 REHABILITATION
7.2.3 CLOTTED BLOOD REMOVAL
7.2.4 WINDOW OPENING IN SKULL
7.2.5 REPAIRING SKULL FRACTURES
7.3 IMMEDIATE EMERGENCY CARE
7.4 MEDICATIONS
7.4.1 DIURETICS
7.4.2 ANTI-SEIZURE DRUGS (ANTI-CONVULSANT)
7.4.3 ANALGESIC
7.4.4 COMA-INDUCING DRUGS
7.4.5 ANTI-DEPRESSANTS
7.4.6 ANTI-ANXIETY AGENT
7.4.7 ANTI-PSYCHOTICS
7.4.8 ANTI-COAGULANTS
7.4.9 OTHERS
7.4.9.1 Parenteral
7.4.9.2 Oral
7.4.9.3 Others
8 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE
8.1 OVERVIEW
8.2 CHILDREN
8.3 TEENAGER
8.4 ELDER
9 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER
9.1 OVERVIEW
9.2 MALE
9.3 FEMALE
10 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, CAUSE OF INJURY
10.1 OVERVIEW
10.2 FALLS
10.3 MOTOR VEHICLE TRAFFIC
10.4 SPORTS
10.5 OTHERS
11 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 NEUROLOGY CLINICS
11.4 INDEPENDENT PHARMACIES
11.5 OTHERS
12 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 INDIA
12.1.4 SOUTH KOREA
12.1.5 AUSTRALIA
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 MALAYSIA
12.1.9 INDONESIA
12.1.10 TAIWAN
12.1.11 NEW ZEALAND
12.1.12 PHILIPPINES
12.1.13 VIETNAM
12.1.14 REST OF ASIA-PACIFIC
13 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 PFIZER INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT/NEWS
15.3 FRESENIUS SE & CO. KGAA (FRESENIUS KABI AG)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 VIATRIS INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 AMNEAL PHARMACEUTICALS LLC
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ADVACARE PHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 AUROBINDO PHARMA LIMITED
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ALEMBIC PHARMACEUTICALS LIMITED
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 B. BRAUN SE
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT UPDATES
15.1 DR. REDDY’S LABORATORIES LTD.
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PIPELINE PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 ICU MEDICAL, INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT/NEWS
15.12 HIKMA PHARMACEUTICALS PLC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PIPELINE PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 JEDUX PARENTERAL PRIVATE LIMITED
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 LUPIN
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 MERZ THERAPEUTICS
15.15.1 COMPANY SNAPSHOT
15.15.2 PIPELINE PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 MAXZIMAA
15.16.1 COMPANY SNAPSHOT
15.16.2 PIPELINE PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SWISS PHARMA NIGERIA LIMITED
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 SAGENT
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
TABLE 1 NON-INVASIVE THERAPEUTIC APPROACHES’ EFFICIENCY IN DIFFERENT PHASES OF TBI
TABLE 2 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC IMMEDIATE EMERGENCY CARE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC CHILDREN IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC TEENAGER IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC ELDER IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC MALE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC FEMALE IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC FALLS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC MOTOR VEHICLE TRAFFIC IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC SPORTS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC OTHERS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC HOSPITALS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC NEUROLOGY CLINICS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC INDEPENDENT PHARMACIES IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC OTHERS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 35 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 36 CHINA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 CHINA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 CHINA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 39 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 40 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 41 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 42 CHINA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 43 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 JAPAN SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 JAPAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 JAPAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 47 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 48 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 49 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 50 JAPAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 51 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 INDIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 INDIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 INDIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 55 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 56 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 57 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 58 INDIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 59 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 60 SOUTH KOREA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 SOUTH KOREA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 SOUTH KOREA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 63 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 64 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 65 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 66 SOUTH KOREA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 67 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 68 AUSTRALIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 AUSTRALIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 AUSTRALIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 71 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 72 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 73 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 74 AUSTRALIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 75 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 76 SINGAPORE SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 SINGAPORE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 SINGAPORE MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 79 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 80 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 81 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 82 SINGAPORE TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 83 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 84 THAILAND SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 THAILAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 THAILAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 87 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 88 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 89 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 90 THAILAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 91 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 92 MALAYSIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 MALAYSIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 MALAYSIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 95 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 96 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 97 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 98 MALAYSIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 99 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 100 INDONESIA SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 INDONESIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 INDONESIA MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 103 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 104 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 105 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 106 INDONESIA TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 107 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 108 TAIWAN SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 TAIWAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 TAIWAN MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 111 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 112 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 113 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 114 TAIWAN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 115 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 116 NEW ZEALAND SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 NEW ZEALAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 NEW ZEALAND MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 119 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 120 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 121 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 122 NEW ZEALAND TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 123 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 124 PHILIPPINES SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 PHILIPPINES MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 PHILIPPINES MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 127 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 128 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 129 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 130 PHILIPPINES TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 131 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 132 VIETNAM SURGERY IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 VIETNAM MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 VIETNAM MEDICATIONS IN TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 135 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE, 2018-2032 (USD THOUSAND)
TABLE 136 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 137 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY CAUSE OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 138 VIETNAM TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END-USER, 2018-2032 (USD THOUSAND)
TABLE 139 REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
Lista de Figura
FIGURE 1 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: MARKET END-USER COVERAGE GRID
FIGURE 9 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING INCIDENCE OF TRAUMATIC BRAIN INJURY (TBI) IS EXPECTED TO DRIVE THE ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 SURGERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DROC ANALYSIS
FIGURE 16 TBI-RELATED DEATHS FROM 2018 TO 2024
FIGURE 17 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 18 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, 2025 TO 2032 (USD THOUSAND)
FIGURE 19 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, CAGR (2025- 2032)
FIGURE 20 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, 2024
FIGURE 22 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, 2025 TO 2032 (USD THOUSAND)
FIGURE 23 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, CAGR (2025- 2032)
FIGURE 24 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY PATIENT AGE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, 2024
FIGURE 26 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 27 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER CAGR (2025-2032)
FIGURE 28 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, 2024
FIGURE 30 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, 2025-2032 (USD THOUSAND)
FIGURE 31 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, CAGR (2025-2032)
FIGURE 32 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY CAUSE OF INJURY, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, 2024
FIGURE 34 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 35 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 36 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 38 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY SHARE 2024 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
